177 related articles for article (PubMed ID: 36614101)
21. Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis.
Wenzler T; Yang S; Braissant O; Boykin DW; Brun R; Wang MZ
Antimicrob Agents Chemother; 2013 Nov; 57(11):5330-43. PubMed ID: 23959303
[TBL] [Abstract][Full Text] [Related]
22. A cathepsin B-like protease is required for host protein degradation in Trypanosoma brucei.
Mackey ZB; O'Brien TC; Greenbaum DC; Blank RB; McKerrow JH
J Biol Chem; 2004 Nov; 279(46):48426-33. PubMed ID: 15326171
[TBL] [Abstract][Full Text] [Related]
23. The mRNA cap methyltransferase gene TbCMT1 is not essential in vitro but is a virulence factor in vivo for bloodstream form Trypanosoma brucei.
Kelner A; Tinti M; Guther MLS; Foth BJ; Chappell L; Berriman M; Cowling VH; Ferguson MAJ
PLoS One; 2018; 13(7):e0201263. PubMed ID: 30040830
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of the natural inhibitor of cysteine peptidases in Leishmania mexicana leads to reduced virulence and a Th1 response.
Bryson K; Besteiro S; McGachy HA; Coombs GH; Mottram JC; Alexander J
Infect Immun; 2009 Jul; 77(7):2971-8. PubMed ID: 19433541
[TBL] [Abstract][Full Text] [Related]
25. Cathepsin-L can resist lysis by human serum in Trypanosoma brucei brucei.
Alsford S; Currier RB; Guerra-Assunção JA; Clark TG; Horn D
PLoS Pathog; 2014 May; 10(5):e1004130. PubMed ID: 24830321
[TBL] [Abstract][Full Text] [Related]
26. Vitamin B12 blocked Trypanosoma brucei rhodesiense-driven disruption of the blood brain barrier, and normalized nitric oxide and malondialdehyde levels in a mouse model.
Oula JO; Mose JM; Waiganjo NN; Chepukosi KW; Mitalo NS; Isaac AO; Nyariki JN
Parasitol Int; 2023 Oct; 96():102775. PubMed ID: 37390918
[TBL] [Abstract][Full Text] [Related]
27. IFN-gamma-dependent nitric oxide production is not linked to resistance in experimental African trypanosomiasis.
Hertz CJ; Mansfield JM
Cell Immunol; 1999 Feb; 192(1):24-32. PubMed ID: 10066343
[TBL] [Abstract][Full Text] [Related]
28. Trypanosome alternative oxidase, a potential therapeutic target for sleeping sickness, is conserved among Trypanosoma brucei subspecies.
Nakamura K; Fujioka S; Fukumoto S; Inoue N; Sakamoto K; Hirata H; Kido Y; Yabu Y; Suzuki T; Watanabe Y; Saimoto H; Akiyama H; Kita K
Parasitol Int; 2010 Dec; 59(4):560-4. PubMed ID: 20688188
[TBL] [Abstract][Full Text] [Related]
29. Should the enzyme name 'rhodesain' be discontinued?
Steverding D; Caffrey CR
Mol Biochem Parasitol; 2021 Sep; 245():111395. PubMed ID: 34246720
[TBL] [Abstract][Full Text] [Related]
30. TNF-alpha mediates the development of anaemia in a murine Trypanosoma brucei rhodesiense infection, but not the anaemia associated with a murine Trypanosoma congolense infection.
Naessens J; Kitani H; Nakamura Y; Yagi Y; Sekikawa K; Iraqi F
Clin Exp Immunol; 2005 Mar; 139(3):405-10. PubMed ID: 15730385
[TBL] [Abstract][Full Text] [Related]
31. Evidence for the occurrence of Trypanosoma brucei rhodesiense sleeping sickness outside the traditional focus in south-eastern Uganda.
Enyaru JC; Odiit M; Winyi-Kaboyo R; Sebikali CG; Matovu E; Okitoi D; Olaho-Mukani W
Ann Trop Med Parasitol; 1999 Dec; 93(8):817-22. PubMed ID: 10715675
[TBL] [Abstract][Full Text] [Related]
32. The pathogenicity of blood stream and central nervous system forms of
Ndungu K; Thuita J; Murilla G; Kagira J; Auma J; Mireji P; Ngae G; Okumu P; Gitonga P; Guya S; Mdachi R
F1000Res; 2022; 11():260. PubMed ID: 38162635
[No Abstract] [Full Text] [Related]
33. Astrocyte activation correlates with cytokine production in central nervous system of Trypanosoma brucei brucei-infected mice.
Hunter CA; Jennings FW; Kennedy PG; Murray M
Lab Invest; 1992 Nov; 67(5):635-42. PubMed ID: 1434541
[TBL] [Abstract][Full Text] [Related]
34. Focus-specific clinical profiles in human African Trypanosomiasis caused by Trypanosoma brucei rhodesiense.
MacLean LM; Odiit M; Chisi JE; Kennedy PG; Sternberg JM
PLoS Negl Trop Dis; 2010 Dec; 4(12):e906. PubMed ID: 21151878
[TBL] [Abstract][Full Text] [Related]
35. Mutual self-defence: the trypanolytic factor story.
Pays E; Vanhollebeke B
Microbes Infect; 2008 Jul; 10(9):985-9. PubMed ID: 18675374
[TBL] [Abstract][Full Text] [Related]
36. Activity of human trypanosome lytic factor in mice.
Barker C; Barbour KW; Berger FG; Hajduk SL
Mol Biochem Parasitol; 2001 Oct; 117(2):129-36. PubMed ID: 11606222
[TBL] [Abstract][Full Text] [Related]
37. The serum resistance-associated gene as a diagnostic tool for the detection of Trypanosoma brucei rhodesiense.
Radwanska M; Chamekh M; Vanhamme L; Claes F; Magez S; Magnus E; de Baetselier P; Büscher P; Pays E
Am J Trop Med Hyg; 2002 Dec; 67(6):684-90. PubMed ID: 12518862
[TBL] [Abstract][Full Text] [Related]
38. The human serum resistance associated gene is ubiquitous and conserved in Trypanosoma brucei rhodesiense throughout East Africa.
Gibson W; Backhouse T; Griffiths A
Infect Genet Evol; 2002 May; 1(3):207-14. PubMed ID: 12798017
[TBL] [Abstract][Full Text] [Related]
39. Only the serum-resistant bloodstream forms of Trypanosoma brucei rhodesiense express the serum resistance associated (SRA) protein.
De Greef C; Chimfwembe E; Kihang'a Wabacha J; Bajyana Songa E; Hamers R
Ann Soc Belg Med Trop; 1992; 72 Suppl 1():13-21. PubMed ID: 1417165
[TBL] [Abstract][Full Text] [Related]
40. Aggravation of pathogenesis mediated by ochratoxin A in mice infected with Trypanosoma brucei rhodesiense.
Kibugu JK; Ngeranwa JJ; Makumi JN; Gathumbi JK; Kagira JM; Mwangi JN; Muchiri MW; Mdachi RE
Parasitology; 2009 Mar; 136(3):273-81. PubMed ID: 19154650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
